| Literature DB >> 18670430 |
Gil Y Melmed, Stephan R Targan, Uma Yasothan, Delphine Hanicq, Peter Kirkpatrick.
Abstract
In April 2008, certolizumab pegol (Cimzia; UCB), a tumour-necrosis factor blocker, was approved by the US FDA for the treatment of adult patients with moderate-to-severe Crohn's disease who have not responded to conventional therapies.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18670430 DOI： 10.1038/nrd2654
Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694